Cascade testing recommended by NICE to find familial hypercholesterolaemia patients
This article was originally published in Scrip
The cascade testing of patients is recommended by the UK health technology assessment agency NICEfor the first time for a common disease in its just-published clinical guideline on identifying and managing familial hypercholesterolaemia.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.